3 Stocks to Buy if You Think the Economy Is Heading for a Recession

The article highlights Abbott Laboratories, Coca-Cola, and Walmart as recession-resistant stocks with durable demand and long dividend track records, including 54, 64, and 53 consecutive years of payout increases, respectively. Abbott is supported by its FreeStyle Libre diabetes franchise and a diagnostics acquisition, while Coca-Cola and Walmart are positioned to benefit from defensive consumer spending and everyday low pricing during an economic downturn. This is largely a stock-selection/opinion piece with limited immediate market impact.

Analysis

This is less a “buy defensives” call than a signal that the market is still pricing recession odds inconsistently across sectors. ABT, KO, and WMT share one important trait: they convert slow-growth environments into operating leverage because demand is sticky, but their valuation upside is usually capped unless the macro backdrop worsens enough to force a rotation out of cyclicals. In other words, these names become relative winners not just in recession, but in the late-cycle phase where earnings revisions for discretionary, industrials, and small-cap retail turn negative first.

The second-order effect is pressure on adjacent competitors with weaker balance sheets or less pricing power. In healthcare, ABT’s resilience can widen the gap versus smaller device and diagnostics players that rely on higher reimbursement growth or elective volume. In staples and retail, KO and WMT are effectively “trade-down beneficiaries”: they can gain share as consumers optimize baskets, which hurts mid-tier brands, regional grocers, and retailers without scale-driven procurement advantages.

The main risk is that this defensives thesis is already partly crowded, especially after a year of periodic recession hedging. If growth stabilizes and inflation keeps easing, the market may rotate back into higher-beta names while the dividend premium in KO/WMT compresses. The real reversal catalyst is not just an absence of recession, but a re-acceleration in nominal GDP over the next 3-6 months that restores confidence in cyclicals and makes low-volatility cash flows less scarce.

Contrarian angle: the article treats dividend durability as the primary edge, but the more interesting opportunity is relative. ABT’s near-term setup looks better than KO or WMT because the market is already penalizing slower top-line growth, so any incremental improvement in diagnostics or device mix could drive multiple expansion from a depressed base. KO and WMT are high-quality, but their defensive premium leaves less room for rerating unless macro data deteriorates further.

Key Decisions for Investors

• Long ABT vs. a basket of recession-exposed healthcare names over 3-6 months; asymmetric if margin stabilization and diagnostics improvement re-rate the stock from a lower growth multiple.
• Use KO as a pair-trade hedge, not a standalone long: long KO / short a consumer discretionary ETF if labor data weakens over the next 1-2 months; better downside capture than outright index hedges.
• Add WMT on pullbacks only; treat it as a 6-12 month ballast position with limited upside, but strong downside protection if consumer spending softens further.
• If the macro backdrop improves, rotate out of KO and WMT into higher-beta cyclicals rather than holding for yield; these names likely underperform by 5-10% on a stable-growth rerating.
• For event-driven positioning, buy short-dated downside protection on weaker regional grocers or mid-tier consumer brands against long WMT exposure; the trade monetizes trade-down share capture if recession fears intensify.